INVO Bioscience, Inc.
INVO
$2.05
$0.21511.75%
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 390.07% | 321.73% | 267.42% | -46.64% | -67.08% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 390.07% | 321.73% | 267.42% | -46.64% | -67.08% |
| Cost of Revenue | 234.59% | 188.52% | 171.85% | 150.01% | 237.11% |
| Gross Profit | 1,040.42% | 1,283.84% | 882.01% | -79.39% | -93.11% |
| SG&A Expenses | -23.05% | -32.42% | -26.05% | -16.09% | -6.32% |
| Depreciation & Amortization | 690.05% | 405.94% | 190.74% | 30.69% | 81.06% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.04% | -14.09% | -14.51% | -10.03% | 0.60% |
| Operating Income | 45.47% | 47.15% | 36.32% | -7.73% | -34.44% |
| Income Before Tax | 30.14% | 33.90% | 26.47% | -9.69% | -27.01% |
| Income Tax Expenses | 434.00% | 920.69% | 858.62% | 23.21% | -10.71% |
| Earnings from Continuing Operations | 29.91% | 33.64% | 26.24% | -9.70% | -26.98% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 29.91% | 33.64% | 26.24% | -6.53% | -26.98% |
| EBIT | 45.47% | 47.15% | 36.32% | -7.73% | -34.44% |
| EBITDA | 51.51% | 50.76% | 37.76% | -7.55% | -34.46% |
| EPS Basic | 85.01% | 72.39% | 52.71% | 9.20% | -15.58% |
| Normalized Basic EPS | 86.32% | 73.63% | 53.21% | 10.79% | -15.85% |
| EPS Diluted | 85.01% | 72.39% | 52.70% | 9.66% | -14.99% |
| Normalized Diluted EPS | 86.32% | 73.63% | 53.21% | 10.79% | -15.85% |
| Average Basic Shares Outstanding | 378.71% | 285.77% | 157.82% | 55.68% | 10.92% |
| Average Diluted Shares Outstanding | 378.71% | 285.77% | 157.82% | 55.68% | 10.92% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
